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Abstract
Purpose: To investigate the variation in computed dose‐volume (DV) indices for
high‐dose‐rate (HDR) prostate brachytherapy that can result from typical differences
in computation settings in treatment planning systems (TPSs).
Methods: Five factors were taken into account: number of dose‐calculation points,
radioactive source description, interpolation between delineated contours, intersec-
tions between delineated organ contours, and organ shape at the top and bottom con-
tour using either full or partial slice thickness. Using in‐house developed software, the
DV indices of the treatment plans of 26 patients were calculated with different set-
tings, and compared to a baseline setting that closely followed the default settings of
the TPS used in our medical center. Studied organs were prostate and seminal vesicles,
denoted as targets, and bladder, rectum, and urethra, denoted as organs at risk (OARs),
which were delineated on MRI scans with a 3.3 mm slice thickness.
Results: When sampling a fixed number of points in each organ, in order to achieve a
width of the 95% confidence interval over all patients of the DV indices of 1% or less,
only 32,000 points had to be sampled per target, but 256,000 points had to be sampled
per OAR. For the remaining factors, DV indices changed up to 0.4% for rectum, 1.3%
for urethra, and 2.6% for prostate. DV indices of the bladder changed especially if the
high‐dose‐region was (partly) located at the most caudal contour, up to 8.5%, and DV
indices of the vesicles changed especially if there were few delineated contours, up to
9.8%, both due to the use of full slice thickness for the top and bottom contour.
Conclusions: The values of DV indices used in prostate HDR brachytherapy treat-
ment planning are influenced by the computation settings in a TPS, especially at the
most caudal part of the bladder, as well as in the seminal vesicles.
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1 | INTRODUCTION
High‐dose‐rate (HDR) brachytherapy is widely applied in the treat-
ment of prostate cancer.1 An important tool in the evaluation and
comparison of HDR prostate brachytherapy treatment plans are
dose‐volume (DV) indices that describe the volumes of different
organs receiving a certain dose. DV indices are an essential part of
recent recommendations and guidelines for HDR prostate
brachytherapy1,2 as well as prospective treatment planning,3 making
an understanding of the accuracy of such indices essential. Potential
uncertainties in these indices should be taken into account when
taking final decisions.
Many clinical and physical factors leading to uncertainties in the
DV indices in brachytherapy in general have already been investi-
gated.4 These include changes in geometry between treatment plan-
ning and delivery, the source strength calibration, and inter‐ and
intra‐observer variability in image delineations of targets, organs at
risk (OARs), and catheters. However, in addition to these uncertain-
ties, settings in the algorithm for the computation of DV indices can
also lead to differences.
A fundamental setting is the number of dose‐calculation points.
The computation of DV indices is usually performed by calculating
the dose in a number of points in the region of interest (ROI, either
a whole organ or part of it) and assuming that these points are rep-
resentative for the entire volume. These dose‐calculation points can
for instance be placed in a regular grid spanning the ROI. However,
the use of random sampling was argued to be superior for calculat-
ing DV indices.5 The number of points and their placement6 influ-
ences the values of the DV indices.
Another setting that can be varied is the source description, con-
sisting of the dosimetric and geometrical data on the radioactive
source. The dose in a point is typically calculated following the TG‐
43 model, to which the source description is an input.7 The source
description is based on previously done Monte Carlo simulations and
measurements. It determines the dose in each dose‐calculation point
and therefore the DV indices. The data in the source description is
not exact, and improvements in simulations and measurements over
time lead to updates in the source description such as mHDR‐v2,8
mHDR‐v2r,9 and mHDR‐v2c,10 revealing an inherent uncertainty in
the source description.
A different type of setting is found in the representation of
organs. The usual input of two‐dimensional contours does not
uniquely define three‐dimensional organs. Therefore, the represented
shape of the organ between two contours depends on the interpola-
tion algorithm used. In the first reported DV histograms (DVHs) cal-
culation method,11 the contours drawn on the two‐dimensional
slices of the medical images were considered to fill the volume
spanned by the scan, i.e., the delineated contour on the 2D slice
was used for the entire slice thickness. Smoother organ surfaces can
be obtained by using continuous interpolation.12
Apart from the interpolation between contours, another setting
in the organ representation is that the intersection between two
organs can be considered to be part of both organs or of only one
of them. Furthermore, the organ shape beyond the top and bottom
contour can be defined by partial or full slice thickness. An example
of a setting with continuous interpolation in combination with top
and bottom contour cut‐off is shown in Fig. 1, together with an illus-
tration of the setting for the intersection between two organs.
In general, variations in the settings for the computation of DV
indices lead to different values and hence potentially to different deci-
sions regarding treatment plans, i.e., to direct clinical impact. More-
over, a comparison of plans between different TPSs is difficult if the
DV computation settings are different. The differences in DV indices
between phantom‐based values and TPSs,13,14 as well as between dif-
ferent commercial TPSs15 have been investigated before. However,
the effects of different settings in the computation of DV indices on
the DV‐index values of actual clinical treatment plans were not ana-
lyzed in such a manner. The aim of this study is to investigate the vari-
ation in computed DV indices that can result from typical differences
in settings for the case of HDR prostate brachytherapy.
2 | METHODS
There are two types of DV indices: volume and dose indices. Volume
indices, i.e., the sub volume of an organ that receives at least (or at
most) a specific dose, are useful for describing the volume of the
tumor that receives a sufficiently high dose. Dose indices, i.e., the
lowest dose to the most irradiated sub volume of a certain size of
an organ, are useful for describing the amount of radiation delivered
to OARs, as well as to targets. In this article, we use the following
notation:
Vax%: the volume of organ a that receives at least x% of the plan-
ning‐aim dose.
Daxcm3: the lowest dose to the most irradiated x cm
3 of organ a.
2.A | Patient data
The patient data consisted of 26 consecutive patients who under-
went prostate HDR brachytherapy at the medical center involved in
this study between February 2015 and April 2017. The median age
was 69.5 years with a range of 58–84. The median Gleason score
was 7 (ISUP grade grouping 2–3) with a range of 6–10 (ISUP grade
grouping 1–5). The urinary flow rate was reported for 23 patients,
with a median of 17 ml/s and a range of 9.6–36.8 ml/s.
After catheter implantation, three orthogonal pelvic T2‐weighted
turbo spin echo MRIs (Ingenia 3T Philips Healthcare, Best, the
Netherlands) were acquired and used for treatment planning, with a
resolution in the axial planes of 0.52 × 0.52 mm and a slice thick-
ness of 3.3 mm (including a 0.3 mm gap). Only the axial slices were
used for catheter reconstruction and delineation of ROIs; coronal
and sagittal slices were used as an aid in the delineation. On most
axial slices manual delineation was performed; on the remaining
slices the delineations suggested by the interpolation algorithm of
the clinical TPS were used. Only the base of the seminal vesicles
was delineated.
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The planning‐aim dose was Dprostate90% >13Gy. A median of 16
catheters was placed with a range of 14–20. The median number of
activated dwell positions was 454.5 with a range of 250–668. The
clinical criteria in terms of the values of DV indices employed in this
study are shown in Table 1.
2.B | Clinical software
The TPS in which the clinically accepted plans for the patient group
were created was Oncentra Brachy (version 4.3 or 4.5, Elekta AB.,
Stockholm, Sweden). In the TPS, DV indices were computed and
evaluated in the “Brachy Planning” module.
2.C | DV computation algorithm
Software for computing the DV indices of each patient used in this
article was in‐house developed and validated with Oncentra Brachy.
Validation was performed by calculating the dose in a fixed set of
points in both systems. For one patient case, 5000 dose calculation
points were equally distributed over the 5 ROIs (Table 1). Excluding
points for which the distance to the active part of the source was
less than 0.5 mm, the difference was below 0.08% of the prescribed
dose.
The input of our in‐house developed software was the following
information:
• Treatment date of the patient for determining the source
strength.
• Delineated contours for the ROIs.
• Catheters information, including coordinates of the implanted
catheters and source dwell positions and dwell times.
• Source information, including TG-43 data describing the source.
In the following sections we describe components of the soft-
ware that play a key role in computing DV indices.
2.C.1 | Dose‐calculation points
The placement of dose‐calculation points was done by uniform ran-
dom sampling inside an ROI. To this end, for each ROI, a bounding box
was created which completely enclosed the ROI. Next, points were
sampled in this box uniformly randomly and only points which were
within the ROI were accepted, i.e., rejection sampling was used. Sam-
pling was continued until the desired number of points inside the ROI
(allowing points to be on the surface of the ROI) was reached.
In the TPS used in our medical center, random sampling is per-
formed with a fixed seed for the random number generator, essen-
tially making the algorithm deterministic. Moreover, a fixed number
of sample points per ROI is used. This approach introduces a depen-
dency of the precision of a DV index on the volume it pertains to,
both for volume indices and for dose indices, in the following way.
For volume indices, when a total of n points is sampled in an
ROI, of which a fraction p consists of the volume corresponding to
the DV index, then the number of points inside the volume of the
DV index follows a binomial distribution. The probability that k of
the n sampling points will be inside the volume of the DV index is
equal to P X ¼ kð Þ ¼ n
k
 
pk 1 pð Þnk with an average of μ ¼ np and
a variance of σ2 ¼ np 1 pð Þ: The closer p is to 0.5, the larger the
variance. Hence, the variance of the DV indices is based on how
close the volume of the DV index is to 50% of the organ volume.
F I G . 1 . Illustration of interpolation algorithm and contour intersection. (a) The interpolation algorithm of the TPS used at our medical center,
applied to delineated contours of a prostate (left) resulting in a three‐dimensional volume (right). (b) An axial slice from a magnetic resonance
imaging (MRI) scan of a patient who underwent prostate brachytherapy with delineated prostate (red), bladder (turquoise), and urethra (green).
The volume of the urethra can either be excluded from or included in the volume of the organ it intersects, namely the prostate.
TAB L E 1 DV indices and clinical criteria used for treatment
planning. All patients involved in this study were treated at our
medical center based on these criteria. Volume criteria V are relative
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For dose indices, when sampling a number of points per ROI, the
variance depends on the number of sample points that are in the
volume of the DV index. This means that the variance of these DV
indices is based on the number of sample points per cm3.
We considered the impact of the number of sample points used
for the dose calculation on the precision of the DV indices. Follow-
ing the approach of the TPS used in our medical center, a fixed num-
ber of sample points per ROI was used. However, in order to
eliminate the dependency of the precision of dose indices on the rel-
evant volumes, we additionally considered using a fixed number of
sample points per cm3 for dose indices.
2.C.2 | Radioactive source description
Dose calculation was based on the update of the AAPM Task Group
No.43 dose formalism.16 The radial dose function and anisotropy
function were based on previously done Monte Carlo simulations of
the 192‐Iridium source. In clinical treatment planning, the mHDR‐v2
source description8 was used. Because of the small design change
made by the manufacturer after this first study, resulting in a small
change to the source used in clinical practice, new dosimetric data has
been provided,9 resulting in the mHDR‐v2r source description. Both
studies were then taken into account in the publishing of a consensus
file, the mHDR‐v2c source description.10 We considered the impact of
using each of these three different source description files.
2.C.3 | Contour interpolation
A straightforward way of defining a three‐dimensional volume from
two‐dimensional contours made on individual slices is to assume that
each contour fills the volume in the z‐direction spanned by the slice
(i.e., slice thickness). This approach assumes that MRI (or computed
tomography, CT) scan slices represent usually an average over the
slice thickness. To obtain smoother organ surfaces, an interpolation
algorithm can be used. In order to study the influence of interpola-
tion, we applied shape‐based interpolation using a chamfer dis-
tance,12 which is the interpolation method implemented in our
clinically used TPS (Fig. 1).
The algorithm used for interpolation between contours of an ROI
used a volume grid.12 For the interpolation between two contours at
height z1 and z2, a two‐dimensional grid was placed on each of the
contours. For each point in a slice, the smallest Euclidean distance to
the contour in that slice was calculated, where the distance is posi-
tive if the point is inside the contour and negative otherwise. Next,
linear interpolation was performed between each pair of correspond-
ing grid points on the two contours to obtain the value of that grid
point at height z = (z1 + z2)/2. Finally, we used the marching squares
algorithm17 to obtain the contour at height z.
For all patients involved in this study, the grid spacing in the clin-
ically used TPS was set to “auto spacing”, giving a spacing of
0.82 mm. The same spacing was used in our software. The interpola-
tion algorithm was used for all pairs of consecutive contours on the
MRI slices. This way, an interpolated contour was added half‐way
between each pair of delineated contours. After this, each contour
was assumed to fill half the volume that the slice spanned.
2.C.4 | Including or excluding contour intersection
The intersection between two contours can be assumed to be
either a part of both ROIs or only a part of one of the ROIs. For
prostate brachytherapy in particular, intersections exist between
the prostate and the urethra, as well as between the bladder and
the urethra. The urethra can thus either be considered to be a part
of both the prostate and the bladder or none of them. The clini-
cally used TPS supports both possibilities. Being part of both
organs is the default option.
Since the urethra passes through the prostate, there is always
overlap between the delineated contours of the urethra and the
prostate. Moreover, for our patient data, there was overlap
between the delineated contours of the urethra and the bladder
as well. The reason for this is that the urethra was delineated as
the part of the urinary catheter through the prostate into the
bladder, due to the fact that the urethra itself is often not well
visible on the MRI. Because our clinical TPS by default considers
the urethra as a part of the organs it intersects, the delineations
of the urethra inside the bladder were redundant, but gave an
overlap between bladder and urethra. All delineations of the ure-
thra, including those inside the bladder, were taken into account
in this study.
2.C.5 | Partial or full top and bottom slice thickness
The organ shape at the top and bottom contour can be defined by
considering the top and bottom slice to fill the volume in the
z‐direction spanned by the slice. In this case, there is full slice
thickness at the most cranially and the most caudally located con-
tour of the organ. Conversely, Oncentra Brachy1 assumes the top
and bottom contour to be part of the surface of the organ: i.e.,
the ROI does not extend beyond the top and bottom contour, and
partial slice thickness is used. The difference between the two set-
tings is relatively large for an organ that consists of only a few
contours, as shown in Fig. 2.
2.D | Volume and dose indices
For the computation of DV indices, the clinically used TPS
employs binning of the DVH. However, in our in‐house devel-
oped software, we used an approach where binning is unneces-
sary.18 For a volume index, the number of dose‐calculation points
where the dose is larger or smaller than a specific dose was
counted. Dividing this number by the total number of dose‐calcu-
lation points in that organ gave the relative volume of an organ
receiving at least or at most that dose. For a dose index, the
dose‐calculation points were sorted from highest to lowest dose.
The dose value of the first point in this sorting that corre-
sponded to the required volume, was returned. For example, if
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1,000 dose‐calculation points are sampled in a urethra of
2.01 cm3, then the Durethra0:1cm3 is determined by the dose of point 50
in the sorted list.
2.E | Analysis
When computing DV indices, we studied the influence of five
factors.
1. The number of dose-calculation points per ROI used in random
sampling.
2. Dosimetric data for mHDR-v2, mHDR-v2r, or mHDR-v2c source
models.
3. Whether interpolation was used between pairs of consecutive
delineated contours.
4. Whether the urethra was considered to be part of the intersect-
ing organs.
5. Full or partial slice thickness inclusion at the top and bottom
contour.
For a given number of dose‐calculation points, we defined a
baseline setting that closely followed the default settings in the clini-
cal TPS. Specifically, in the baseline setting, the mHDR‐v2 dosimetric
data was used, the urethra was considered part of the prostate and
bladder, contour interpolation was used, and partial slice thickness
was used at the top and bottom contour.
Because the number of dose‐calculation points was not a cate-
gorical variable, we first studied this factor separately, using the
baseline settings for the other factors. By considering the number of
points that were actually located inside an organ, the result was
independent of the bounding box that was used for sampling points
in that organ.
For a given number of dose‐calculation points, the DV indices
were computed 100 times using a pseudo‐random number generator
with different random seeds (the Mersenne Twister 1993719). The
variance was used to calculate the width of a 95% confidence inter-
val (CI). Since the sampled points follow a binomial distribution
which rapidly converges to a normal distribution for many dose‐cal-
culation points, a normal distribution was assumed. The result was
averaged over all patients.
The DV indices were computed for 1,000–256,000 dose‐calcula-
tion points for both targets and OARs, each step doubling the num-
ber of dose‐calculation points. The DV indices of the OARs were
additionally computed with a fixed number of dose‐calculation points
per cm3, where the total number of dose‐calculation points in these
organs depended on the delineated volume of each of the ROIs. The
DV indices were computed for 10–2,560 dose‐calculation points per
cm3, each step doubling the number of dose‐calculation points. For
each number of dose‐calculation points, the result was averaged
over all patients.
By using a large number of dose‐calculation points, the true
influence of the remaining factors could be studied. We fixed the
number of dose‐calculation points to 256,000 per target, and the
number of dose‐calculation points in OARs to 2,560 dose‐calculation
points per cm3. First, we studied only the impact of changing the
dosimetric data from mHDR‐v2 to either mHDR‐v2r or mHDR‐v2c.
Then, we studied the impact of the remaining three factors, which
resulted in a total of eight possible settings. All results were com-
pared to the baseline setting. For the most influential factors, the
influence compared to the baseline setting was tested using a paired
statistical test, selected based on the data. The significance threshold
was set at 0.01. Normality of the data of two variables was tested
using a Q‐Q plot; symmetry of the data was tested using a boxplot
of the difference between two variables.
3 | RESULTS
The width of the 95% CI of each DV index as a function of the
number of dose‐calculation points when considering the baseline
setting is shown in Fig. 3. When the number of dose‐calculation
points is fixed per target, the ordering of the confidence interval of





100% , i.e., ordered on how close on average the volume
of the DV index is to 50% of the organ volume. When the number
of dose‐calculation points is fixed per cm3, the total number per
OAR depends on the OAR volume. The average delineated volume
of each of the ROIs in the baseline setting is shown in Table 2.
The differences over all patients for the setting of the dosimetric
data of the source with respect to the baseline setting for DV
indices of prostate, seminal vesicles, and OARS, are very small. The
maximum difference was observed for the seminal vesicles with
0.94% (Supplementary material, Fig. S1).
The differences in the other settings are shown in Fig. 4.
Because the urethra was delineated as the urinary catheter, there
could be overlap between the ROI delineated as the urethra, and the
bladder. The most sensitive DV indices were found to be the Vvesicles80% ,
and the Dbladder1cm3 and D
bladder
2cm3 for the bladder. Multiple settings resulted
in a Vvesicles80% which was lower than in the baseline setting. Vice versa,
multiple settings resulted in a Dbladder1cm3 and D
bladder
2cm3 which were higher
than in the baseline setting. For all three DV indices, the treatment
plan thus appeared to be worse in other settings than in the baseline
setting. In extreme cases, as shown in Fig. 4(c), the difference could
become an increase of 6.7% in the Dbladder2cm3 , an increase of 8.5% in
the Dbladder1cm3 , and a decrease of 9.8% in the V
vesicles
80% with respect to
the baseline setting.
F I G . 2 . Illustration of slice thickness. Full top and bottom slice
thickness (left) versus partial slice thickness (right) for an ROI with
three delineated contours (in orange). The difference in resulting
volume consists of the gray parts in the left shape.
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Moreover, for the prostate, the Vprostate150% and D
prostate
90% were also
relatively sensitive as shown in Fig. 4(d). The sensitivity of the DV
indices of rectum and urethra was within the variance of the number
of dose‐calculation points.
For the prostate, the inclusion or exclusion of the urethra was
the most important factor [Fig. 4(a)]. On average, the amount of
radiation to the urethra was between 100% and 110% of the plan-
ning‐aim dose. The relative volume of the urethra that received
100% of the planning‐aim dose was close to the relative volume of
the prostate (excluding the urethra) that received 100% of the plan-
ning‐aim dose, so the Vprostate100% remained similar after exclusion of the
urethra. However, an important factor in making the treatment plans
was urethra sparing, i.e., minimizing the dose to the urethra. There-
fore, the dose in the urethra was on average lower than the dose in
the prostate (excluding the urethra). Hence, excluding the urethra
increased the Dprostate90% .
For the Vprostate150% and the V
prostate
200% , the relative volume receiving
over 150% or 200% of the planning‐aim dose is used. However, the
absolute volume receiving over 150% or 200% of the planning‐aim
dose was in practice independent of whether the urethra was
included in the prostate. Since the DV index was calculated with
respect to the total volume, the larger this total volume, the larger
the difference in DV index between including and excluding the ure-
thra. Since the volume receiving over 150% of the planning‐aim dose
includes the volume receiving over 200% of the planning‐aim dose,
the Vprostate150% was more sensitive to urethra exclusion than the
Vprostate200% .
For the two most influential factors, the difference compared to
the baseline setting was tested using a paired statistical test based







were normally distributed, hence a paired samples t‐test was used.
The 95% CI of the difference between inclusion and exclusion of
the urethra in the prostate was (1.1, 1.5) for the Vprostate150% (P < 0.001)
and (0.8, 1.4) for the Dprostate90% (P < 0.001). Concerning the difference
between full and partial slice thickness, for the bladder it was (0.6,
2.4) for the Dbladder1cm3 (P = 0.002), and (0.6, 2.1) for the D
bladder
2cm3
(P = 0.001). The data of the Vvesicles80% was not normally distributed,
nor was the difference symmetrical in shape, hence a paired‐samples
sign test was used. For the Vvesicles80% , there was a statistically signifi-
cant median decrease using full slice thickness (−2.6%) compared to
partial slice thickness (P < 0.001).
4 | DISCUSSION
In this study, the influence of computation settings on the resulting
DV indices of clinically optimized HDR prostate brachytherapy plans
was investigated. These settings were related to number of dose‐cal-
culation points, dosimetric data (source models), and organ represen-
tation, and can differ between TPSs2,15. Differences in DV indices of
up to 9.8% were observed.
4.A | Dose‐calculation points
The study showed that a large number of dose‐calculation points is
required for the DV indices of the OARs to be accurate (i.e., have lit-
tle uncertainty). When sampling a fixed number of points in an
organ, in order to achieve a width of the 95% CI of 1% or less, only
32,000 points have to be sampled per target, but 256,000 points
F I G . 3 . The uncertainty in the DV indices for targets and OARs as a function of the number of dose‐calculation points. The width of the
95% confidence interval (CI) is either in percentage of total ROI volume for volume indices V, or percentage of planning‐aim dose
(Dprostate90% >13Gy) for dose indices D. On top the result for the targets (prostate and seminal vesicles) is shown. On the bottom the result for the
OARs is shown. The dotted lines indicate the upper bound on the width of the 95% CI for the highest number of dose‐calculation points.
TAB L E 2 The volume of targets and OARs over all patients,
determined in the baseline setting.
ROI Average (cm3) Minimum (cm3) Maximum (cm3)
Prostate 33.97 16.46 71.09
Seminal vesicles 4.08 0.51 11.79
Bladder 98.48 44.50 264.64
Rectum 54.04 23.16 108.54
Urethra 2.08 0.51 3.81
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have to be sampled per OAR. This is due to the use of dose indices
of an absolute volume which is small compared to the total volume
of the OAR, such as the Dbladder1cm3 .
The large number of dose‐calculation points that is required
for the DV indices of OARs to reach high accuracy is in accor-
dance with previous studies,6 where it was recommended not to
use the Dmin and the Dmax to describe dose distributions because
of their large sensitivity to the number of dose‐calculation points.
More dose‐calculation points result in a more accurate result, but
also a slower calculation. The uncertainty of grid sampling versus
random sampling has been studied before and is in general even
higher.5
4.B | Radioactive source description
The maximum difference resulting from different dosimetric data of
the source8–10 was observed for the seminal vesicles with 0.94%,
making this uncertainty in the range of the uncertainty of the dose‐
calculation points. A newer version of the dosimetric data can be
assumed to be better, but the influence of this setting is negligible.
4.C | Organ intersections
The setting in our study that influenced the DV indices of the pros-
tate the most was whether or not to include the urethra in the pros-
tate. Excluding the urethra from the prostate increased the DV
indices of the prostate, especially the Dprostate90% and the V
prostate
150% with
medians of 1.0%, respectively, 1.2%.
This setting differs between TPSs. Oncentra Brachy by default
considers the urethra to be part of the prostate. In contrast, Oncen-
tra Prostate excludes the urethra from the prostate, as well as
Vitesse, a TPS specifically for HDR prostate (Varian Medical Systems,
Charlottesville, VA, USA).
This setting should be carefully considered by a medical center,
before designing treatment plans based on a certain clinical protocol.
Excluding the urethra from the prostate not only influences the DV
index values, it also affects the clinical dose aims used during treat-
ment planning that apply to the urethra. If the urethra is included in
the prostate, then the requirement Vprostate100% >95% comprises the dose
to the urethra as well. However, if the urethra is excluded from the
prostate, then the only aim would be Durethra0:1cm3<110% of the planning‐
aim dose. Due to uncertainties, it could then be prudent to define a
lower limit on the dose, e.g., on Durethra0:1cm3.
4.D | Contour interpolation and slice thickness
inclusion at the outer contours
For the settings of both contour interpolation and slice thickness at
the outer contours, especially the DV indices of the seminal vesicles
and the bladder were sensitive. Without the use of contour interpo-
lation, the median difference in the DV indices was at most 0.75%,
which was observed for the Dbladder1cm3 . Extremes were at most 2.5%,
observed for both the Vvesicles80% and the D
bladder
1cm3 . Using full top and
bottom slice thickness, a median decrease of 2.6% was seen for the
Vvesicles80% . Extremes include an increase of 8.5% for the D
bladder
1cm3 , and a
decrease of 9.8% for the Vvesicles80% .
F I G . 4 . The sensitivity of DV indices for
both targets and OARs to different ROI
representation settings. Each result is
relative to the baseline setting. The change
in DV index is presented as percentage of
total ROI volume for volume indices V, or
percentage of planning‐aim dose
(Dprostate90% >13Gy) for dose indices D. Dotted
lines show the 95% CI associated with the
uncertainty related to the sampling of
dose‐calculation points. Each boxplot
shows the distribution over all patients
(median at 50%, box from 25% to 75%,
whiskers at 0% and 100%).
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For the seminal vesicles, the sensitivity of the DV indices to
these settings could be explained by the small target volume, in
combination with the large surface of the top and bottom contour.
This is also because usually only the base of the vesicles is delin-
eated. For the bladder, the most irradiated 1 cm3 and 2 cm3 were
often exactly at the bottom contour. The importance of the 3D
reconstruction algorithm at the outer slices has been noted before in
a phantom study.15
Still, settings differ between different TPSs. Oncentra Brachy
uses interpolation in combination with partial slice thickness. Vitesse
uses a different interpolation algorithm, also in combination with
partial slice thickness. Other TPSs of Varian use again different set-
tings. VariSeed uses full slice thickness, whereas BrachyVision has
been reported to round the ends of cylinder edges contained within
the last slice15 because of the use of interpolation where ROI
boundaries are smoothed.
This uncertainty can be improved by using a smaller slice thick-
ness, that can be obtained without loss of anatomic detail,20 and
delineating more contours. In addition, the evaluation of a treatment
plan is often a combination of evaluating the DV indices and visually
inspecting the projections of the 3D dose distribution on the MRI
scans. Especially if the high‐dose region of the bladder is (partly)
located at the bottom contour, and/or the seminal vesicles have few
delineated contours, their DV indices may be unreliable to evaluate
a treatment plan. The visual inspection of the 3D dose distribution
especially at the boundary area of the bladder, as well as in the vesi-
cles, is then needed for a reliable evaluation.
4.E | Clinical impact
A limitation of this study is that it is a single‐center study. The
described treatment plans were optimized in our clinical TPS (i.e.,
Oncentra Brachy) with its default settings and could give different
results if the treatment plans had been optimized in other TPSs.
However, our finding that computation settings can influence the
DV index values is general. The clinical relevance of this uncertainty
in the DV index values depends on the total planned dose. If
patients receive brachytherapy next to external beam radiotherapy,
the deviations are a smaller part of the total dose than if brachyther-
apy is given as monotherapy. The study is limited to prostate
brachytherapy, but similar results may occur even for different treat-
ment sites.
This study has been performed retrospectively. However, compu-
tation settings may influence the optimization process inherent in
treatment planning, be it manual or automated.21,22 It would be
interesting to also consider the magnitude of this influence on the
optimization process and the outcome thereof. Moreover, treatment
plan optimization could possibly be adapted to account for this influ-
ence by applying robust optimization to these uncertainties. Treat-
ment plan optimization whereby the influence of different
computation settings is accounted for, is suggested as future work.
5 | CONCLUSIONS
The values of DV indices used in prostate HDR brachytherapy treat-
ment planning are influenced by the computation settings in a TPS,
especially at the most caudal part of the bladder, as well as in the
seminal vesicles, potentially to an extent that it could influence deci-
sions on final treatment plan construction.
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1 Nucletron B.V., Oncentra Brachy v4.5 Physics and Algorithms.
2 Nucletron B.V., Oncentra Brachy v4.5 Physics and Algorithms.
Nucletron B.V., Oncentra Prostate v4.2 Reference Manual.
Varian Medical Systems, Inc., Vitesse v4.5 Reference Guide.
Varian Medical Systems, Inc., Brachy Vision 15.5 Algorithms Reference
Guide.
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Supporting Information section at the end of the article.
Fig. S1. The sensitivity of DV indices for both targets and OARs
to different source models, relative to the baseline setting (mHDR‐
v28). The change in DV index is presented as percentage of total
ROI volume for volume indices V, or percentage of planning‐aim
dose (Dprostate90% >13Gy) for dose indices D. Dotted lines show the 95%
confidence interval associated with the uncertainty related to the
sampling of dose‐calculation points. Each boxplot shows the distribu-
tion 10 over all patients (median at 50%, box from 25% to 75%,
whiskers at 0% and 100%).
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